The validity of death certificates: routine validation of death certification and its effects on mortality statistics

Lahti, R.A; Penttilä, Antti

doi:10.1016/s0379-0738(00)00300-5

Cited by 228 publications

(165 citation statements)

References 16 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…The accuracy and consistency of death cer tif icates and other sources of mortality data have been debated. [8][9][10] Both ESRD registry reports and death certif icates are key sources of infor mation for planning preventive and treatment services for renal disease. Consistent with the findings of Perneger and colleagues in Maryland, US, 6 we have shown substantial differences between cause-of-death reports in two Australian national information systems for the same ESRD population, even at the broad ICD-10 chapter level.…”

Section: Discussionmentioning

confidence: 99%

Cause of death in patients with end‐stage renal disease: assessing concordance of death certificates with registry reports

Cass

Cunningham

2003

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cause of death in patients with end‐stage renal disease: assessing concordance of death certificates with registry reports

Cass

Cunningham

2003

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

show abstract

“…No entanto, pesquisas atuais 5 no país não demonstram melhora significativa nestes percentuais. Nos países desenvolvidos, o mau preenchimento das DOs é verificado em maior magnitude em relação à causa de óbito, para onde a maior parte das pesquisas converge [19][20][21][22][23][24][25] . Lomuto 26 , na Argentina, relata o registro deficiente da idade gestacional comprometendo a análise do percentual de baixo peso e prematuridade.…”

Section: Discussionunclassified

Qualidade dos dados sobre óbitos neonatais precoces

Pedrosa¹,

Sarinho²,

Ximenes³

et al. 2007

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

A cobertura e confiabilidade do SIM são características essenciais que lhe conferem credibilidade, mas que ficam comprometidas pela subnotificação de eventos, preenchimento incorreto e incompleto da DO, presença de discordâncias e quando há elevado percentual de variáveis ignoradas. Incompletas, suas informações podem distorcer os indicadores gerados, a ponto de transmitir uma falsa idéia de adequação das condições de saúde locais 2 . As variáveis da DO, utilizadas na geração de indicadores, são classificadas para efeito de crítica e correção pelo Sistema em indispensáveis: tipo e data do óbito; essenciais: sexo, idade e município de residência; e secundárias: todas as demais, inclusive as de preenchimento exclusivo para óbitos fetais e em menores de um ano 4 . A omissão dos antecedentes obstétricos em óbitos neonatais pode ocasionar sub-estimativa dos eventos ocorridos na gestação e parto, que culminam com as causas maternas, na maioria, evitáveis 3 . Alagoas detém o maior índice de mortalidade infantil do país (com taxa de 55,57/1000 nascidos vivos em 2001, e de 52,64 /1000 nascidos vivos em 2002 8 ) e não dispõe de estudos que avaliem a qualidade das informações oficiais de óbitos neonatais.O objetivo do estudo é avaliar a qualidade do Sistema de Informações sobre Mortalidade, por meio do estudo das variáveis da Declaração de Óbito e de dados de correspondente transcrição dessas variáveis em campos dos registros do sistema.

show abstract

“…Data of purchased statin prescriptions for study periods included the following information: subject ID, date of purchase, amount purchased (in defined daily dose, DDD) [15], and ATC (Anatomical Therapeutic Chemical) for drug. Information of dates and causes of death was obtained from Statistics Finland [16]. The follow-up started when first statin prescription was purchased and ended 31-12-2009 or death, which ever occurred first.…”

Section: Study Population and Data Sourcesmentioning

confidence: 99%

Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings

Niskanen¹,

Suvisaari²,

Suvisaari³

et al. 2013

View full text Add to dashboard Cite

Purpose: The aim was to study discontinuation of statin treatment, especially with respect to clinical characteristics and adverse effect measured by clinical laboratory tests indicating muscle damage (plasma creatine kinase, CK) and liver AEs (plasma alanine aminotransferase, ALAT). Methods: The initial study population included 60,488 individuals who had purchased first time statin prescription in Helsinki-Uusimaa region between 01-01-2007 and 31-12-2009. The follow-up started when first statin prescription was purchased and ended 31-12-2009 or death, which ever occurred first. From this population 54,172 individuals were defined to eligible to study population of this study. Clinical laboratory measurements were obtained from Helsinki-Uusimaa University Hospital (HUSLAB) that which provides the laboratory tests for the Helsinki-Uusimaa region serving about a population of 1.5 million. Results: In this fairly large real-life study the occurrence of ALAT-AE and mild CK-elevations after initiation of first statin treatments were relatively low. Increasing age and the presence of co-morbidities increased the risk of these AEs. Further, the ALAT-AEs implied increased risk of discontinuation of treatment. Diabetic patients discontinued treatment more often than nondiabetics, whereas the presence of other chronic conditions implied higher persistence of statin treatment. Conclusions: It is essential that those who would benefit from statin therapy actually are treated and by far in most patients treatment seems to be safe and well tolerated. For those who cannot tolerate statins new therapeutic options are needed.

show abstract

The validity of death certificates: routine validation of death certification and its effects on mortality statistics

Cited by 228 publications

References 16 publications

Cause of death in patients with end‐stage renal disease: assessing concordance of death certificates with registry reports

Cause of death in patients with end‐stage renal disease: assessing concordance of death certificates with registry reports

Qualidade dos dados sobre óbitos neonatais precoces

Discontinuation of Statin Treatment in Relation to Chronic Diseases and Laboratory Findings

Contact Info

Product

Resources

About